SpaceX Files for IPO Aiming to Raise $80 Billion
SpaceX and OpenAI are moving toward blockbuster public debuts, with SpaceX formally filing its Form S 1 to list on Nasdaq under the ticker "SPCX" in what could become the largest IPO in history. Meanwhile, OpenAI is reportedly preparing to submit its own draft prospectus as early as this week for a potential September listing.LATEST IPOS AND DIRECT LISTINGS:Conexeu Sciencesopened on May 21 at $13.50 after a Nasdaq direct listing. The preclinical developer of a regenerative tissue device for wound care and aesthetics filed a resale prospectus with the SEC stating that it expected its common stock to begin trading on the Nasdaq on or about Thursday, May 21, in connection with its direct listing. The company registered 9.5M shares that may be sold by the Registered Securityholders identified in the prospectus. Conexeu Sciences will not raise new capital in its listing. The stock opened for trading earlier at a price of $13.50 per share.Lincoln Internationalopened on May 20 at $22.51. The company priced 21.05M shares at $20.00, at the top end of the $18.00-$20.00 target range. Lincoln International is an investment banking advisor whose services include mergers and acquisitions advisory, private funds and capital markets advisory, and valuations and fairness opinions.Amass Brandsopened on May 20 at $17 after a Nasdaq direct listing. The premium, multi-category beverage platform spanning non-alcohol, functional, and alcohol 2.0 products saw its common stock begin trading earlier on the Nasdaq Capital Market under the stock ticker symbol "AMSS". The direct listing did not involve the issuance of new common stock by the company, it noted.Optimi Healthopened on May 20 at $5.50 after a Nasdaq uplisting. The commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products announced the pricing of its underwritten public offering in connection with the uplisting of its common shares to the Nasdaq Capital Market. The company offered 2.4M common shares at a public offering price of $6.25 per share.RECENT SPAC IPOS:Peace Acquisitionopened on May 22 at $10.01. The blank check company intends to focus its search on businesses throughout Asia. "However, the Company will not undertake an initial business combination with any entity based in or with its principal business operations in Mainland China, Hong Kong or Macau," it added.Aperture ACopened on May 21 at $10.01. The blank check company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.Research Alliance Corporation IIIopened on May 20 at $10.21. The blank check company intends to focus its search on a target business in the healthcare or healthcare-related industries.Amanat Acquisitionopened on May 19 at $10.15. While the company may pursue an initial business combination target in any business or industry, it intends to focus on opportunities in healthcare or healthcare-related industries.PERFORMANCE:Prices as of 10:15 am ET on Monday, May 26 -Conexeu Sciences – down about 5% at $13.70;Lincoln International – down more than 2% at $23.52;Amass Brands – down almost 11% at $3.85;Optimi Health – down about 5% at $5.57.RECENT IPOS TO WATCH:Pershing Square Inc., Pershing Square USA, Avalyn Pharma, Hemab Therapeuticsand Seaport Therapeuticsare already seeing coverage roll out, while Silver Bow Miningis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include SpaceX, Sunshine Silver Mining & Refining, Innio, Inspire Brands, and Tarsier Pharma.Clickto see upcoming IPO calendar on TipRanks.SpaceXofficially submitted its Form S-1 with the SEC to list its Class A common stock on the Nasdaq under the ticker symbol SPCX. Expected to be the largest IPO in history, the company targets raising up to $80B at a valuation exceeding $2T.Sunshine Silver Mining & Refining Companyannounced the launch of its initial public offering of 20M shares of its common stock. In connection with the offering, Sunshine expects to grant the underwriters a 30-day option to purchase up to 3,000,000 shares of common stock. The IPO price is expected to be between $13.50-$16.50 per share. Sunshine's common stock has been approved for listing, subject to official notice of issuance, under the ticker symbol "SSMR" on the New York Stock Exchange.Innioannounces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common shares. The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. Innio has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Innio designs, manufactures and services power systems under its Jenbacher and Waukesha brands. The company delivers power for applications including data centers, microgrids, grid stabilization, industrial energy and gas compression.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated: "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial."OTHER IPO NEWS:OpenAI is preparing to file for a public listing as early as this week, with the AI lab aiming for a blockbuster initial public offering as soon as September, Financial Times' George Hammond. The company has been laying the groundwork for an offering expected to value it at north of $1T, working with bankers at Morgan Stanleyand Goldman Sachsand lawyers at Cooley over the past few months, according to people familiar with the matter. The group could file a draft IPO prospectus as early as Friday, starting the timer on a public listing for the autumn, they added. That timing could shift depending on the market and on the performance of Elon Musk's SpaceX, which is expected to go public next month in the biggest listing of all time, the author notes.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on CNXU
About CNXU
About the author

- Preclinical Milestone: Conexeu Sciences Inc. has completed the P.R.O.O.F phase of its CXU preclinical program, establishing an evidence base for its entry into the approximately $11 billion medical aesthetics injectable market, marking a strategic move into this emerging field.
- Surging Market Demand: The GLP-1 drug market reached approximately $79 billion in 2025 and is projected to double to about $190 billion by 2035, driving a demand for tissue restoration that current injectable tools cannot meet, which Conexeu aims to address.
- Significant Growth Potential: The company anticipates the market for treating GLP-1-related concerns will grow from about $0.7 billion in 2025 to $2.0 billion by 2030, positioning Conexeu as an early mover to capitalize on this rapidly expanding market opportunity.
- Accelerated Regulatory Path: Conexeu plans to submit a 510(k) application in Q1 2027, leveraging the FDA's expedited review pathway, although there is no assurance that the FDA will accept the submission on time, which will lay the groundwork for its commercialization.
- Market Opportunity Analysis: Conexeu Sciences Inc. has completed the P.R.O.O.F phase of its CXU preclinical program, marking a strategic entry into the approximately $11 billion medical aesthetics injectable market, which is expected to grow rapidly due to the popularity of GLP-1 drugs.
- Identifying Industry Gaps: With the weight-loss drug market reaching $79 billion in 2025 and projected to double to $190 billion by 2035, Conexeu highlights that existing aesthetic tools cannot address the facial and body volume loss resulting from rapid weight loss, creating a new market opportunity.
- Clinical Research Outcomes: The P.R.O.O.F phase included studies on small and large volume applications, successfully meeting objectives across three evidence pillars, laying the groundwork for CXU's market positioning, although peer review has not yet occurred and clinical significance remains unestablished.
- Regulatory Path Planning: Conexeu plans to submit a 510(k) application in Q1 2027, utilizing a fast-track review process based on previously cleared devices to expedite market entry and establish CXU commercially, although there remains uncertainty regarding FDA acceptance.
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
- New R&D Center Launch: Conexeu Sciences has opened a new research and development facility at the 30,000-square-foot M4 Innovation Centre in Vancouver, marking a significant milestone in the company's growth and expected to enhance its capabilities in regenerative tissue technology.
- Advancement of Technology Platforms: The new lab will focus on advancing the CXU™ regenerative tissue platform and B.R.E.A.S.T.™, a 3D bioprinted breast matrix designed to improve tissue regeneration outcomes post-mastectomy, potentially enhancing patient treatment results.
- Significant Market Potential: Conexeu's CXU™ platform targets multi-billion-dollar markets, including wound care and facial contouring, with a 510(k) submission anticipated in early 2027, demonstrating the company's strong confidence in market expansion.
- Strong Leadership Team: Conexeu is managed by a leadership team with deep expertise in biomaterials and regenerative medicine, committed to driving the commercialization of medical devices and further solidifying its position in the life sciences industry.
- Market Size Forecast: Independent estimates indicate that the regenerative medicine market will reach tens of billions of dollars by 2026, with projections to exceed $100 billion within a decade, reflecting a compound annual growth rate often estimated in the high teens to mid-20s percent, showcasing rapid growth potential in the sector.
- Scientific Shift: The field is transitioning from traditional tissue replacement to regeneration, utilizing biomaterials, cell therapies, and 3D bioprinting technologies aimed at enabling the body to heal itself, thereby enhancing treatment outcomes and patient quality of life.
- Demographic Drivers: The aging population, diabetes epidemic, and increasing incidence of chronic non-healing wounds are driving demand for regenerative solutions, particularly in aesthetics and reconstructive surgery, leading to a diversified market need.
- Industry Complexity: The regenerative medicine sector faces multiple challenges including reimbursement policies, regulatory pathways, and manufacturing scale, as evidenced by recent upheaval in the U.S. skin substitute market, highlighting the significant impact of payer policies on company profitability and the need for adaptability in response to market changes.
- Market Growth: The regenerative medicine market is projected to reach tens of billions of dollars by 2026, with forecasts suggesting it could exceed $100 billion within a decade, reflecting a compound annual growth rate often estimated in the high teens to mid-20s percent range, indicating substantial commercial potential.
- Scientific Shift: The field is transitioning from traditional tissue replacement to regeneration, utilizing biomaterials and cell therapies to help the body heal itself, thereby enhancing treatment outcomes and improving patient quality of life.
- Demographic Demand Drivers: The aging population and the rise of chronic diseases like diabetes are increasing the need for tissue repair, particularly in trauma and reconstructive surgery, which is driving market demand for regenerative solutions.
- Policy and Market Complexity: Despite the promising market outlook, changes in policy and regulatory pathways are crucial for company success, as evidenced by recent upheaval in the U.S. skin substitute market, highlighting the significant impact of reimbursement policies on revenue.








